Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
LEXINGTON, Mass., July 8, 2024 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that on July 1, 2024, the independent Compensation Committee of the Board of Directors of Curis approved the grant of inducement stock options to purchase a total of 25,000 shares of Curis common stock to a new employee, with a grant date of July 1, 2024 (the "Q3 2024 Inducement Grant").
2024年7月8日，馬薩諸塞州列剋星敦市 /美通社/--Curis股份有限公司（納斯達克：CRIS）是一家專注於開發可口服、小分子IRAK4抑制劑emavusertib（CA-4948）的生物技術公司。今天公告稱，Curis獨立薪酬委員會於2024年7月1日批准向新員工授予招致期權，以購買共計25,000股Curis普通股，授予日爲2024年7月1日（"Q3 2024招致期權")。
The Q3 2024 Inducement Grant has an exercise price per share equal to the closing price of the Company's common stock on July 1, 2024. The stock option has a 10 year term and vests over four years, with 25% of the original number of shares underlying the award vesting on the first anniversary of the employee's date of hire and an additional 6.25% of the original number of shares underlying the award vesting on each successive three-month period thereafter, subject to the employee's continued service with the Company through the respective vesting dates. The stock option was granted as an inducement equity award outside of the Company's Fifth Amended and Restated 2010 Stock Incentive Plan and was made as an inducement material to the employee's acceptance of employment with the Company.
“Q3 2024招致期權”的行權價格等於公司普通股票於2024年7月1日的收盤價格。該期權有10年期限，分四年歸屬，即獎項原有股數的25%在員工入職後的第一週年紀念日歸屬，之後每三個月追加歸屬獎項原有股數的6.25%，前提是員工在各自的歸屬日繼續在公司任職。該期權是作爲公司的第五次修訂和重訂2010年股份激勵計劃外的招致權益獎項授予的，是員工接受公司就業所必需的招致物。
About Curis, Inc.
關於Curis公司 Curis是一家專注於開發可口服、小分子IRAK4抑制劑emavusertib的生物技術公司。目前，emavusertib正在接受第1/2期TakeAim淋巴瘤研究的測試，用於治療復發/難治的原發性中樞神經系統淋巴瘤(PCNSL)，與BTk抑制劑ibrutinib聯合使用，在復發/難治急性髓細胞白血病（AML）和復發/高風險骨髓增生異常綜合徵（hrMDS）攜帶FLT3基因突變或剪切因子突變的（U2AF1或SF3B2）患者中作爲單藥治療，並作爲與azacitidine和venetoclax聯合前線治療AML的組合療法。Emavusertib已獲美國食品和藥物管理局的孤兒藥品認證，用於治療AML和MDS。Curis通過其與Aurigene的2015年合作，擁有emavusertib（CA-4948）的獨家許可。Curis將其Erivedge的權利授權給羅氏集團成員Genentech，他們正在商業化Erivedge治療晚期基底細胞癌。欲了解更多信息，請訪問Curis公司的網站。
Curis is a biotechnology company focused on the development of emavusertib, an orally available, small molecule IRAK4 inhibitor. Emavusertib is currently undergoing testing in the Phase 1/2 TakeAim Lymphoma study in patients with relapsed/refractory primary central nervous system lymphoma (PCNSL) in combination with the BTK inhibitor ibrutinib, as a monotherapy in the Phase 1/2 TakeAim Leukemia study in patients with relapsed/refractory acute myeloid leukemia (AML) and relapsed/refractory high risk myelodysplastic syndrome (hrMDS) with either a FLT3 mutation or a splicing factor mutation (U2AF1 or SF3B2), and as a frontline combination therapy with azacitidine and venetoclax in patents with AML. Emavusertib has received Orphan Drug Designation from the U.S. Food and Drug Administration for the treatment of AML and MDS. Curis, through its 2015 collaboration with Aurigene, has the exclusive license to emavusertib (CA-4948). Curis licensed its rights to Erivedge to Genentech, a member of the Roche Group, under which they are commercializing Erivedge for the treatment of advanced basal cell carcinoma. For more information, visit Curis's website at .
Curis是一家專注於開發可口服、小分子IRAK4抑制劑emavusertib的生物技術公司。Emavusertib目前正在接受測試，用於治療復發/難治的原發性中樞神經系統淋巴瘤(PCNSL)，與BTk抑制劑ibrutinib聯合使用，在復發/難治急性髓細胞白血病（AML）和復發/高風險骨髓增生異常綜合徵（hrMDS）攜帶FLT3基因突變或剪切因子突變的（U2AF1或SF3B2）患者中作爲單藥治療，並作爲與azacitidine和venetoclax聯合前線治療AML的組合療法。Emavusertib已獲美國食品和藥物管理局的孤兒藥品認證，用於治療AML和MDS。Curis通過其與Aurigene的2015年合作，擁有emavusertib（CA-4948）的獨家許可。Curis將其Erivedge的權利授權給羅氏集團成員Genentech，他們正在商業化Erivedge治療晚期基底細胞癌。
SOURCE Curis, Inc.
來源：Curis，Inc。